More recent data from the Evolut Low Risk Trial confirmed a decreasing trend in post-procedural AKI rates amongst TAVI patients, with only 0.9% of participants developing stage 2 or 3 AKI [ 5 ].
← all excerpts
Contrast Volume-to-Estimated Glomerular Filtration Rate Ratio as a Predictor of Short-Term Outcomes Following Transcatheter Aortic Valve Implantation.
1
—
—